CA3113167A1 - Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation - Google Patents
Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation Download PDFInfo
- Publication number
- CA3113167A1 CA3113167A1 CA3113167A CA3113167A CA3113167A1 CA 3113167 A1 CA3113167 A1 CA 3113167A1 CA 3113167 A CA3113167 A CA 3113167A CA 3113167 A CA3113167 A CA 3113167A CA 3113167 A1 CA3113167 A1 CA 3113167A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- liquid pharmaceutical
- rpl554
- composition according
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816447.5 | 2018-10-09 | ||
| GB1816447.5A GB2578093B (en) | 2018-10-09 | 2018-10-09 | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| PCT/GB2019/052863 WO2020074894A1 (en) | 2018-10-09 | 2019-10-09 | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3113167A1 true CA3113167A1 (en) | 2020-04-16 |
Family
ID=64394831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3113167A Pending CA3113167A1 (en) | 2018-10-09 | 2019-10-09 | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20210379053A1 (https=) |
| EP (2) | EP3820446B1 (https=) |
| JP (2) | JP7578587B2 (https=) |
| KR (1) | KR20210073532A (https=) |
| CN (1) | CN112912064B (https=) |
| AU (1) | AU2019358585B2 (https=) |
| BR (1) | BR112021006712A2 (https=) |
| CA (1) | CA3113167A1 (https=) |
| CY (1) | CY1124943T1 (https=) |
| DK (1) | DK3820446T3 (https=) |
| ES (1) | ES2899744T3 (https=) |
| GB (1) | GB2578093B (https=) |
| HR (1) | HRP20220053T1 (https=) |
| HU (1) | HUE057780T2 (https=) |
| IL (1) | IL282032B1 (https=) |
| LT (1) | LT3820446T (https=) |
| MX (2) | MX2021003599A (https=) |
| MY (1) | MY207302A (https=) |
| PH (1) | PH12021550767A1 (https=) |
| PL (1) | PL3820446T3 (https=) |
| PT (1) | PT3820446T (https=) |
| RS (1) | RS62775B1 (https=) |
| SG (1) | SG11202102567UA (https=) |
| SI (1) | SI3820446T1 (https=) |
| SM (1) | SMT202200044T1 (https=) |
| WO (1) | WO2020074894A1 (https=) |
| ZA (1) | ZA202102039B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3142701T3 (en) | 2014-05-12 | 2018-08-13 | Verona Pharma Plc | New treatment |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB201916915D0 (en) | 2019-11-20 | 2020-01-01 | Amr Centre Ltd | Compounds |
| GB2594480A (en) * | 2020-04-28 | 2021-11-03 | Verona Pharma Plc | New treatment |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| WO2024088364A1 (zh) * | 2022-10-28 | 2024-05-02 | 江苏恒瑞医药股份有限公司 | 一种包含异喹啉酮类化合物的药物组合物及其制备方法 |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| CN121620356A (zh) | 2023-06-26 | 2026-03-06 | 维罗纳制药公司 | 包含恩塞芬汀的颗粒组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2208310T3 (es) | 1999-03-31 | 2004-06-16 | Vernalis Limited | Derivados de pirimido(6,1-a) isoquinolin-4-ona. |
| PH12013500261A1 (en) * | 2010-08-09 | 2013-03-04 | Verona Pharma Plc | Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound |
| EP2819645A2 (en) * | 2012-02-28 | 2015-01-07 | Iceutica Holdings Inc. Bvi | Inhalable pharmaceutical compositions |
| EP2968313B1 (en) | 2013-03-15 | 2018-01-31 | Verona Pharma PLC | Drug combination |
| DK3142701T3 (en) * | 2014-05-12 | 2018-08-13 | Verona Pharma Plc | New treatment |
| CN110051627A (zh) * | 2014-09-15 | 2019-07-26 | 维罗纳制药公司 | 包含rpl554的液体吸入制剂 |
| GB201502260D0 (en) * | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
-
2018
- 2018-10-09 GB GB1816447.5A patent/GB2578093B/en active Active
-
2019
- 2019-10-09 WO PCT/GB2019/052863 patent/WO2020074894A1/en not_active Ceased
- 2019-10-09 JP JP2021517866A patent/JP7578587B2/ja active Active
- 2019-10-09 CN CN201980065895.8A patent/CN112912064B/zh active Active
- 2019-10-09 PT PT197907181T patent/PT3820446T/pt unknown
- 2019-10-09 KR KR1020217010706A patent/KR20210073532A/ko active Pending
- 2019-10-09 MX MX2021003599A patent/MX2021003599A/es unknown
- 2019-10-09 SG SG11202102567UA patent/SG11202102567UA/en unknown
- 2019-10-09 HU HUE19790718A patent/HUE057780T2/hu unknown
- 2019-10-09 EP EP19790718.1A patent/EP3820446B1/en active Active
- 2019-10-09 LT LTEPPCT/GB2019/052863T patent/LT3820446T/lt unknown
- 2019-10-09 DK DK19790718.1T patent/DK3820446T3/da active
- 2019-10-09 ES ES19790718T patent/ES2899744T3/es active Active
- 2019-10-09 BR BR112021006712-4A patent/BR112021006712A2/pt unknown
- 2019-10-09 MY MYPI2021001479A patent/MY207302A/en unknown
- 2019-10-09 PL PL19790718T patent/PL3820446T3/pl unknown
- 2019-10-09 SI SI201930145T patent/SI3820446T1/sl unknown
- 2019-10-09 US US17/280,452 patent/US20210379053A1/en not_active Abandoned
- 2019-10-09 EP EP21198029.7A patent/EP3960157A1/en active Pending
- 2019-10-09 SM SM20220044T patent/SMT202200044T1/it unknown
- 2019-10-09 AU AU2019358585A patent/AU2019358585B2/en active Active
- 2019-10-09 HR HRP20220053TT patent/HRP20220053T1/hr unknown
- 2019-10-09 RS RS20211599A patent/RS62775B1/sr unknown
- 2019-10-09 CA CA3113167A patent/CA3113167A1/en active Pending
-
2021
- 2021-03-25 ZA ZA2021/02039A patent/ZA202102039B/en unknown
- 2021-03-26 MX MX2024001499A patent/MX2024001499A/es unknown
- 2021-04-04 IL IL282032A patent/IL282032B1/en unknown
- 2021-04-06 PH PH12021550767A patent/PH12021550767A1/en unknown
-
2022
- 2022-02-02 CY CY20221100086T patent/CY1124943T1/el unknown
-
2024
- 2024-03-26 US US18/616,878 patent/US20250049781A1/en active Pending
- 2024-06-05 JP JP2024091837A patent/JP7836853B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250049781A1 (en) | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation | |
| EP2435024B1 (en) | Compositions for respiratory delivery of active agents and associated methods and systems | |
| CA2835927A1 (en) | Compositions, methods & systems for respiratory delivery of two or more active agents | |
| US20200163955A1 (en) | Sterile compositions of indacaterol suitable for nebulization | |
| US20160310410A1 (en) | Pharmaceutical compositions comprising arformoterol and glycopyrronium | |
| KR20120100901A (ko) | 포모테롤 및 베클로메타손 디프로피오네이트의 약학적 에어로졸 제제 | |
| HK40061834A (en) | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation | |
| RU2813959C2 (ru) | Фармацевтические композиции, содержащие RPL554 в HFA-134A для введения посредством ингаляции | |
| US20090180969A1 (en) | Pharmaceutical formulation comprising an anticholinergic drug | |
| HK40042852B (en) | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation | |
| HK40042852A (en) | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation | |
| HK1169027B (en) | Compositions for respiratory delivery of active agents and associated methods and systems | |
| HK1169307B (en) | Respiratory delivery of active agents | |
| HK1228797B (en) | Compositions for respiratory delivery of active agents and associated methods and systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220927 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240815 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240905 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240905 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240905 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241206 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250205 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250604 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250604 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260324 |